Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 3/2008

01-09-2008

Differential Expression of Dysadherin in Papillary Thyroid Carcinoma and Microcarcinoma: Correlation with E-cadherin

Authors: Anna Batistatou, Konstantinos Charalabopoulos, Yukihiro Nakanishi, Constantine Vagianos, Setsuo Hirohashi, Niki J. Agnantis, Chrissoula D. Scopa

Published in: Endocrine Pathology | Issue 3/2008

Login to get access

Abstract

Dysadherin is a novel glycoprotein, with an anti-cell–cell adhesion function. The aim of the present study was to examine the expression of dysadherin in thyroid papillary microcarcinoma (PMC), to associate it with the expression of E-cadherin and to investigate whether there are differences with papillary carcinoma (PC). A statistically significant difference in dysadherin and E-cadherin expression between PC and PMC and a negative correlation between E-cadherin and dysadherin expression regardless of tumor size were noted. Based on these findings it is hypothesized that retained cell–cell adhesion, through maintenance of the E-cadherin adhesion system, in PMC prevents neoplastic cells from dissociating easily from each other and metastasizing. Increased dysadherin expression is possibly one of the post-transcriptional mechanisms responsible for E-cadherin downregulation in thyroid papillary neoplasia.
Literature
1.
2.
Scopa CD. Histopathology of thyroid tumors. An overview. Hormones 3:100–10, 2004.PubMed
3.
4.
5.
Piersanti M, Ezzat S, Asa SL. Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol 14:183–91, 2003.PubMedCrossRef
6.
7.
8.
9.
Tetzlaff MT, Liu A, Xu X, Master SR, Balwin DA, Tobias JW, Livolsi VA, Baloch ZN. Differential expression of miRNAs in papillary thyroid carcinoma compared in formalin fixed paraffin embedded tissues. Endocr Pathol 18:163–73, 2007. doi:10.​1007/​s12022-007-0023-7.PubMedCrossRef
10.
Abrosimov A, Saenko V, Meirmarov S, Nakashima M, Rogounocitch T, Shkurko O, Lushnikov E, Mitsutake N, Namba H, Yamashita S. The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histological variants and its correlation with cyclin D1 overexpression. Endocr Pathol 18:68–75, 2007. doi:10.​1007/​s12022-007-0012-x.PubMedCrossRef
11.
12.
Charalabopoulos K, Binolis J, Karkabounas S. Adhesion molecules in carcinogenesis. Exp Oncol 24:249–57, 2002.
13.
14.
Serini G, Trusolino L, Saggiorato E, Cremona O, De Rossi M, Angeli A, Orlandi F, Marchisio PC. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst 88:442–9, 1996. doi:10.​1093/​jnci/​88.​7.​442.PubMedCrossRef
15.
von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Pötter E, Brabant G, Georgii A. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57:2501–7, 1997.
16.
Kapran Y, Ozbey N, Molvalilar S, Sncer E, Dizdaroglu F, Ozarmagan S. Immunohistochemical detection of E-cadherin, alpha- and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest 25:578–85, 2002.PubMed
17.
Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simoes M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42:580–7, 2002. doi:10.​1046/​j.​1365-2559.​2003.​01642.​x.CrossRef
18.
19.
Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB, Saji M, Zeiger MA, Zimmer SG, Baylin SB. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell and poorly differentiated human thyroid carcinoma. Cancer Res 58:2063–6, 1998.PubMed
20.
21.
Fu X, Kamps MP. E2A-Pbx1 induces aberrant expression of tissue specific and developmentally regulated genes when expressed in NIH 3T3 fibroblasts. Mol Cel Biol 17:1503–12, 1991.
22.
Batistatou A, Peschos D, Tsanou H, Charalabopoulos A, Nakanishi Y, Hirohashi S, Agnantis NJ, Charalabopoulos K. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Br J Cancer 96:1404–8, 2007.PubMed
23.
Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura J, Soma T, Ino Y, Nakanishi Y, Sakamoto M, Hirohashi S, Imamura M. Clinical significance of dysadherin expression in gastric cancer patients. Clin Cancer Res 10:2818–23, 2004. doi:10.​1158/​1078-0432.​CCR-0633-03.PubMedCrossRef
24.
Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato Y, Kitajima M, Sakamoto M, Hirohashi S. Prognostic significance of dysadherin expression in advanced colorectal carcinoma. Br J Cancer 88:726–32, 2003. doi:10.​1038/​sj.​bjc.​6600778.PubMedCrossRef
25.
Batistatou A, Charalabopoulos A, Scopa CD, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch 448:763–7, 2006. doi:10.​1007/​s00428-006-0183-8.PubMedCrossRef
26.
27.
Shimada Y, Hashimoto Y, Kan T, Kawamura J, Okumura T, Soma T, Kondo K, Teratani N, Watanabe G, Ino Y, Sakamoto M, Hirohashi S, Imamura M. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology 67:73–80, 2004. doi:10.​1159/​000080289.PubMedCrossRef
28.
Sato H, Ino Y, Miura A, Abe Y, Sakai H, Ito K, Hirohashi S. Dysadherin: expression and clinical significance in thyroid carcinoma. J Clin Endocrinol Metabol 88:4407–12, 2003. doi:10.​1210/​jc.​2002-021757.CrossRef
29.
Nakanishi Y, Akimoto S, Sato Y, Kanai Y, Sakamoto M, Hirohashi S. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases. Appl Immunohistochem Mol Morphol 12:323–8, 2004. doi:10.​1097/​00129039-200412000-00006.PubMed
30.
Kyzas P, Stefanou D, Batistatou A, Agnantis NJ, Nakanishi Y, Hirohashi S, Charalabopoulos K. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphagiogenesis and prognostic significance. Am J Surg Pathol 39:185–93, 2006. doi:10.​1097/​01.​pas.​0000178090.​54147.​f8.
31.
Batistatou A, Scopa CD, Ravazoula P, Nakanishi Y, Peschos D, Agnantis NJ, Hirohashi S, Charalabopoulos KA. Involvement of dysadherin and E-cadherin in the development of testicular tumors. Br J Cancer 93:1382–7, 2005. doi:10.​1038/​sj.​bjc.​6602880.PubMedCrossRef
32.
Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathol Oncol Res 10:212–8, 2004.PubMedCrossRef
33.
Nishizawa A, Nakanishi Y Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma. Cancer 103:1693–700, 2005. doi:10.​1002/​cncr.​20984.PubMedCrossRef
34.
Nam J-S, Kang M-J, Suchar A, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66:7176–84, 2006. doi:10.​1158/​0008-5472.​CAN-06-0825.PubMedCrossRef
35.
Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metabol 87:1810–3, 2002. doi:10.​1210/​jc.​87.​4.​1810.CrossRef
36.
Ito Y, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A. p130 expression in thyroid neoplasms: its linkage with tumor size and dedifferentiation. Cancer Lett 192:83–7, 2003. doi:10.​1016/​S0304-3835(02)00627-4.PubMedCrossRef
37.
Ito Y, Suzuki T, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Yamamoto T, Miyauchi A. Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. Cancer Lett 220:237–42, 2005. doi:10.​1016/​j.​canlet.​2004.​08.​017.PubMedCrossRef
38.
Khoo MLC, Beasley NJP, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metabol 87:1814–8, 2002. doi:10.​1210/​jc.​87.​4.​1814.CrossRef
39.
Metadata
Title
Differential Expression of Dysadherin in Papillary Thyroid Carcinoma and Microcarcinoma: Correlation with E-cadherin
Authors
Anna Batistatou
Konstantinos Charalabopoulos
Yukihiro Nakanishi
Constantine Vagianos
Setsuo Hirohashi
Niki J. Agnantis
Chrissoula D. Scopa
Publication date
01-09-2008
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 3/2008
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-008-9035-1

Other articles of this Issue 3/2008

Endocrine Pathology 3/2008 Go to the issue

OriginalPaper

Diagnostic Controversies in Vascular Proliferations of the Thyroid Gland

OriginalPaper

Poorly Differentiated Thyroid Carcinoma: Diagnostic Features and Controversial Issues

OriginalPaper

Molecular Detection of PPARγ Rearrangements and Thyroid Carcinoma in Preoperative Fine-Needle Aspiration Biopsies

ReviewPaper

The Genomic Revolution and Endocrine Pathology

CASE

True Adrenal Mesothelial Cyst in a Patient with Flank Pain and Hematuria

OriginalPaper

Expression of p21cip1, p27kip1, and p16INk4a Cyclin-Dependent Kinase Inhibitors in Papillary Thyroid Carcinoma: Correlation with Clinicopathological Factors
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits